Muñ oz NM, Meliton AY, Meliton LN, Dudek SM, Leff AR. Secretory group V phospholipase A2 regulates acute lung injury and neutrophilic inflammation caused by LPS in mice. Am J Physiol Lung Cell Mol Physiol 296: L879 -L887, 2009. First published March 13, 2009 doi:10.1152/ajplung.90580.2008.-We investigated the regulatory role of 14-kDa secretory group V phospholipase A2 (gVPLA2) in the development of acute lung injury (ALI) and neutrophilic inflammation (NI) caused by intratracheal administration of LPS. Experiments were conducted in gVPLA2 knockout (pla2g5 Ϫ/Ϫ ) mice, which lack the gene, and gVPLA2 wild-type littermate control (pla2g5 ϩ/ϩ ) mice. Indices of pulmonary injury were evaluated 24 h after intratracheal administration of LPS. Expression of gVPLA2 in microsections of airways and mRNA content in lung homogenates were increased substantially in pla2g5 ϩ/ϩ mice after LPS-administered compared with saline-treated pla2g5 ϩ/ϩ mice. By contrast, expression of gVPLA2 was neither localized in LPS-nor saline-treated pla2g5 Ϫ/Ϫ mice. LPS also caused 1) reduced transthoracic static compliance, 2) lung edema, 3) neutrophilic infiltration, and 4) increased neutrophil myeloperoxidase activity in pla2g5 ϩ/ϩ mice. These events were attenuated in pla2g5 Ϫ/Ϫ mice exposed to LPS or in pla2g5 ϩ/ϩ mice receiving MCL-3G1, a neutralizing MAb directed against gVPLA2, before LPS administration. Our data demonstrate that gVPLA2 is an inducible protein in pla2g5 ϩ/ϩ mice but not in pla2g5 Ϫ/Ϫ mice within 24 h after LPS treatment. Specific inhibition of gVPLA2 with MCL-3G1 or gene-targeted mice lacking gVPLA 2 blocks ALI and attenuates NI caused by LPS. airway inflammation; chemotaxis; pulmonary compliance SECRETORY PHOSPHOLIPASE A2S (PLA 2 ) are a family of lipolytic enzymes that catalyze the cleavage of fatty acids from the sn-2 position of phospholipids leading to the generation of free fatty acids and lysophospholipids (6, 9, 20, 27, 33, 36, 38) . There are at least 12 isoforms of secreted PLA 2 in mice (27, 33, 36, 38 
mice. LPS also caused 1) reduced transthoracic static compliance, 2) lung edema, 3) neutrophilic infiltration, and 4) increased neutrophil myeloperoxidase activity in pla2g5 ϩ/ϩ mice. These events were attenuated in pla2g5 Ϫ/Ϫ mice exposed to LPS or in pla2g5 ϩ/ϩ mice receiving MCL-3G1, a neutralizing MAb directed against gVPLA2, before LPS administration. Our data demonstrate that gVPLA2 is an inducible protein in pla2g5 ϩ/ϩ mice but not in pla2g5 Ϫ/Ϫ mice within 24 h after LPS treatment. Specific inhibition of gVPLA2 with MCL-3G1 or gene-targeted mice lacking gVPLA 2 blocks ALI and attenuates NI caused by LPS. airway inflammation; chemotaxis; pulmonary compliance SECRETORY PHOSPHOLIPASE A2S (PLA 2 ) are a family of lipolytic enzymes that catalyze the cleavage of fatty acids from the sn-2 position of phospholipids leading to the generation of free fatty acids and lysophospholipids (6, 9, 20, 27, 33, 36, 38) . There are at least 12 isoforms of secreted PLA 2 in mice (27, 33, 36, 38) ; all of these isoforms are expressed in humans. Among the secreted PLA 2 s, gIIaPLA 2 , gVPLA 2 , and gXPLA 2 have been implicated in a variety of inflammatory lung diseases, e.g., acute lung injury (3, 10, 21, 40) , acute respiratory distress syndrome (11, 37) , sepsis (1, 41) , and asthma (12, 24, 30) . However, the relative contributions of secretory PLA 2 s in these diseases remain unclear, as disparate findings have been demonstrated (3, 12, 24, 27, 30, 37, 40, 41) .
Increased concentrations of gIIaPLA 2 are detected in sepsis (1, 41) , rheumatoid arthritis (34) , and ARDS (11, 37) . However, LY-31592ONA/S-5920 ({[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy} acetate), an inhibitor of 14-kDa secretory PLA 2 s, did not improve survival in patients with severe sepsis (41) , even though LY-31592ONA/S-5920 blocked oleic acid-induced acute lung injury (ALI) in rabbits (10) . Previous investigations have reported that snake venom sPLA 2 causes ALI in rats (31, 35) and that this enzyme hydrolyzes phospholipids in lung surfactant (5) .
Secretory gVPLA 2 is a 14-kDa protein and structurally similar to gIIaPLA 2 (6, 20, 27, 33, 38) . However, gVPLA 2 has ϳ50-fold the hydrolytic capacity for outer cell surface phosphatidylcholine-rich plasma membrane compared with gIIaPLA 2 in cell-free systems (13, 15) . gVPLA 2 is a proinflammatory enzyme that has diverse biological effects including airway inflammation (24) , airway hyperresponsiveness (24) , cell adhesion (25, 39) , transcellular communication (25, 39) , and generation of lipid mediators (4, 16, 17, 23, 25, 32, 39) .
Secretory gVPLA 2 , which is not expressed in eosinophils (23, 25, 26, 39) , is contained in neutrophils, epithelial cells, airway smooth muscle, T cells, and macrophages (7, 14, 20, 24 -27, 33, 36) . There is no known receptor for gVPLA 2 (4, 20, (23) (24) (25) (26) (27) 33) ; gVPLA 2 binds to the outer cell membrane due to its high affinity to its interfacial binding site located at Trp-31 (13, 16, 17, (23) (24) (25) . Mutation of Trp-31 to alanine reduces the hydrolytic activity of gVPLA 2 (13, 16, 17, (23) (24) (25) . Internalization of gVPLA 2 by binding to heparan sulfate proteoglycan further hydrolyzes the nuclear membrane adding more arachidonic metabolites to the external membrane hydrolysis products, which have been taken up by the cell (16) .
Deletion of the gene encoding gVPLA 2 attenuates eosinophilic infiltration and airway hyperresponsiveness in allergic mice (24) . However, there have been no studies on the effects of gVPLA 2 in ALI and neutrophilic inflammation (NI). In this study, we investigated the effect of LPS-induced gVPLA 2 on ALI and NI using pla2g5 Ϫ/Ϫ knockout (KO) and pla2g5 ϩ/ϩ littermate control mice. We found 1) that gVPLA 2 synthesis is induced by LPS administration and 2) an association between gVPLA 2 activity and the severity of ALI as measured by change in pulmonary compliance, neutrophilic infiltration, and neutrophil activation. Our data are the first demonstration that 14-kDa secretory gVPLA 2 is an intracellular messenger protein in regulating LPS-induced vascular leak in mice in vivo.
MATERIALS AND METHODS

Animals
Homozygous gVPLA2 KO (pla2g5 Ϫ/Ϫ ) and littermate control (pla2g5 ϩ/ϩ ) were derived from C57/BL6 mice as previously described (4, 32) . C57BL/6 mice, aged 10 -12 wk old, were maintained on standard laboratory chow ad libitum. pla2g5 Ϫ/Ϫ were bred in the University of Chicago Animal Facility. Briefly, mice heterozygous for disruption of the gene encoding group V sPLA 2 (pla2g5) were crossed to a C57/BL6 background. Mating pairs of pla2g5 Ϫ/Ϫ and pla2g5 ϩ/ϩ mice were derived from the litters of C57/BL6 heterozygous breeding pairs. Experimental protocols conformed to the principles outlined by the Animal Welfare and the National Health services guidelines for the care and use of animal in biomedical research and were approved by the University of Chicago IACUC Review Board.
RT-PCR
An ϳ2-mm tail piece was cut from each weaning. DNA was isolated, and genotyping was performed using PCR. Mice with the required genotype, gVPLA 2 littermate control (pla2g5 ϩ/ϩ ) and gVPLA2 KO (pla2g5 Ϫ/Ϫ ), were kept until immunologically mature. Primers used for gVPLA2 were forward, 5Ј-GATGCACGACCGTTGTTATG-3Ј, reverse, 5Ј-TAATCTAATGGAAGAGCCTCAGGT-3Ј.
Determination of gVPLA2 expression
mRNA expression for gVPLA2. Total RNA was isolated using TRIzol reagent (Life Technologies, Rockville, MD). cDNA was synthesized using 0.5 g of total RNA in a 20-l reverse transcriptase reaction using iScript cDNA synthesis kit (Bio-Rad Laboratories; Hercules, CA). The primers for gVPLA 2 were sense 5Ј-GTAACCCGTTGAACCCCATT-3Ј, antisense 5Ј-GGTCTAGAGTCAGTCACACTTGGGCG-3Ј.
Immunohistochemistry. Lungs were fixed by inflation with 10% paraformaldehyde solution at a pressure of 20 cmH 2O and embedded in paraffin. Briefly, lung tissues, ϳ5-to 6-m-thick sections, were subsequently cut and processed as previously described (24) . Endogenous peroxidase activity and nonspecific antibody binding were prevented by incubating the tissue section for 15 min in 0.5% hydrogen peroxide solution, methanol (vol/vol), and normal goat serum (1/5 dilution). Slides containing lung tissues were incubated for 1 h in primary antibody (MCL-3G1) or IgG 1 antibody (negative control) diluted in normal saline solution (26) . Antibody binding was localized with a biotinylated secondary antibody, avidin-conjugated HRP, and diaminobenzidine chromogenic substrate (Vector Laboratories, Burlingame, CA). Stained airway microsections prepared from treated pla2g5 ϩ/ϩ or pla2g5 Ϫ/Ϫ mice were examined for the presence of gVPLA2 using light microscopy.
Murine Model of ALI
Preparation of LPS. Purified LPS from Escherichia coli (SigmaAldrich, St. Louis, MO) was dissolved in 10 ml of endotoxin-free saline. The mixed solution was placed in a 37°C shaking water bath for 30 min and was subjected to sonication for 2 min in an ultrasonic water bath to obtain a homogenous solution. The LPS stock solution was aliquoted to the desired volume and stored in Ϫ20°C. The final dose of LPS used in this study was 10 mg/kg per intratracheal administration.
Preparation of animals. gVPLA 2 wild-type littermate control (pla2g5 ϩ/ϩ ) and KO (pla2g5 Ϫ/Ϫ ) mice were anesthetized with ketamine-xylazine (100 mg/kg:20 mg/kg) (24) and were instilled through a catheter inserted into the trachea with either sterile saline solution or 10 mg/kg LPS. The dose of LPS was chosen to be consistent with previous studies wherein the greatest neutrophil emigration in the lungs was achieved. Animals were studied 24 h after administration of LPS.
Generation of Pressure-Volume Curves (Transthoracic Static Compliance)
Mice weighing 25-32 g were anesthetized with intraperitoneal ketamine-xylazine (100 mg/kg:20 mg/kg). The animals were placed in a supine position, and a tracheostomy was performed using an 18-gauge needle secured with a 3-0 suture. The intubated animal was connected to a computer-controlled small animal ventilator (Flexivent; Scireq, Vancouver, Canada) that delivered a tidal volume of 6 ml/kg at a frequency of 120 breaths/min (24); the mice were allowed to breathe 100% oxygen for 5 min. The ventilator was stopped, and the tube connected to the trachea was clamped to ambient air. Lungs were inflated with Ն30 cmH 2O transthoracic pressure, and volume was gradually decreased in 0.1-ml increments. The static lung compliance was determined by recording the lung pressure change associated with each volume change in the system when the trachea was occluded to ambient air (zero flow). Two or more full inflationdeflation cycles were determined for each mouse to achieve a volume history, and the pressure-volume characteristics of the lungs were generated.
Determination of Wet:Dry Weight Ratio (Lung Fluid Accumulation)
Animals treated as above were killed, and lungs were immediately excised, blotted dry, and weighed. Lung dry weights were recorded after treatment in an oven for 7 days at 65°C. The lung wet:dry weight ratio was determined by dividing the wet weight by the dry weight. The data were normalized to wild-type (WT) control where 1 ϭ 0 represents no fluid accumulation in the lung.
Total and Differential Inflammatory Cell Counts
NI was assessed 24 h after LPS treatment in
Ϫ/Ϫ mice alone. The trachea was exposed and cannulated with an 18-gauge needle; bronchoalveolar lavage (BAL) was performed by injecting 0.8 ml of PBS into the lung and gently aspirating the fluid. The procedure was performed 3ϫ to recover a total volume of 2-3 ml. The BAL fluid samples were centrifuged to obtain the cell pellet until analysis. Cytoslides were prepared and stained with Diff-Quick (Dade Diagnostics, Deerfield, IL), and the total and differential cells counts were determined using a hemocytometer (24) .
BAL cells were harvested, and the number of migrated neutrophils was determined by flow cytometric analysis. Briefly, cells were washed with cold FACS buffer (PBS with 1% BSA and 0.1% NaN3) and centrifuged at 400 g for 10 min. The pellets were washed with FACS buffer once before adding 4 l of Gr-1 (clone RB6-8C5; EBioscience, San Diego, CA), a MAb that has been used to identify monocytes and peripheral blood PMNs. Thirty minutes later, the cells were washed 3ϫ with FACS buffer and incubated with FITC-conjugated goat anti-mouse Ig for 30 min at 4°C. Treated cells were fixed in 1% paraformaldehyde solution until analysis (22) .
Determination of Total Lung MPO Content
The activity of neutrophil MPO (22) was determined from homogenized lungs of treated animals. MPO activity was proportional to the content of MPO in PMNs obtained from BAL fluid. Briefly, 50 l of lung homogenates was added to 100 l of HBSS ϩ 10% FBS buffer and 100 l of developing solution (8 ml 100 nM NaH2PO4, pH 5.5, 1,000 l 10% hexadecyltrimethyammonium bromide, 3 l 30% hydrogen peroxide, 1,000 l 10% o-dianisidine dihydrochloride). The reaction mixture was terminated by addition of 50 l of sulfuric acid; absorbance was measured at 405 nm in a microplate reader (Thermomax; Molecular Devices, Menlo Park, CA). A standard curve was generated on each sample plate, and linear regression curve was generated.
Data Analysis
All values were expressed as means Ϯ SE. The Student's t-test was used for comparison between two groups. When more than two groups were compared, differences among the groups were determined by one-way ANOVA. The differences between groups were considered significant if P Ͻ 0.05.
RESULTS
Expression of Secretory gVPLA 2
We first examined the expression of gVPLA 2 in airway microsections obtained from gVPLA 2 wild-type littermate control (pla2g5 ϩ/ϩ ) mice 24 h after LPS administration. Representative photomicrographs (n ϭ 6) demonstrated that LPS caused upregulation of gVPLA 2 expression as determined by immunohistochemical staining (Fig. 1) . Intracellular gVPLA 2 was detected in abundant quantities in microsections of pla2g5 ϩ/ϩ airways receiving LPS (Fig. 1A) . gVPLA 2 was weakly expressed in saline-treated pla2g5 ϩ/ϩ airways or parenchyma (Fig. 1B ) compared with LPS-treated pla2g5 ϩ/ϩ mice. Expression of gVPLA 2 , as indicated by dark brown color, was evident in peripheral airways and lung parenchyma (Fig. 1A) . IgG 1 , an isotype-matched, irrelevant antibody, was used as negative control (Fig. 1, A and B) .
To confirm further the specificity of MAb directed against gVPLA 2 , airway microsections from saline-and LPS-treated gVPLA 2 -KO mice (pla2g5 We next determined the mRNA expression for gVPLA 2 in lung tissues obtained from these same animals by RT-PCR analysis (32) . In pla2g5 ϩ/ϩ mice, mRNA expression for gVPLA 2 was upregulated after LPS exposure compared with saline-exposed mice (Fig. 2) . All data were normalized per 18S housekeeping gene and expressed as the ratio of gVPLA 2 mRNA/18S. mRNA expression for gVPLA 2 was 0.97 Ϯ 0.36-fold/18S for pla2g5 ϩ/ϩ mice after LPS administration compared with baseline control expression of 0.48 Ϯ 0.20-fold/18S for saline-treated pla2g5 ϩ/ϩ mice (P Ͻ 0.05). By contrast, mRNA expression for gVPLA 2 was 0.006 Ϯ 0.002-fold/18S for pla2g5 Ϫ/Ϫ mice after LPS treatment (P Ͻ0.001 vs. LPStreated pla2g5 ϩ/ϩ mice) and 0.005 Ϯ 0.002-fold/18S for pla2g5 Ϫ/Ϫ mice having saline treatment (P Ͻ0.001 vs. LPStreated pla2g5 ϩ/ϩ mice).
Transthoracic Static Compliance: Pressure-Volume Curves
We next measured the transthoracic static compliance, an index of lung edema caused by ALI. Pressure-volume (P-V) curves were generated in 1) saline-treated pla2g5 ϩ/ϩ mice (n ϭ 7 mice), 2) LPS-treated pla2g5 ϩ/ϩ mice (n ϭ 8 mice),
3) LPS-treated pla2g5
Ϫ/Ϫ mice (n ϭ 6 mice), and 4) MCL-3G1 plus LPS-treated pla2g5 ϩ/ϩ mice (n ϭ 5 mice) in vivo. Lung volume in experimental animals was measured begin- Representative photomicrographs from 6 airway microsections of pla2g5 ϩ/ϩ mice were shown that gave similar results. Original magnification, ϫ100 pixel. Ab, antibody.
ning at Ն30 cmH 2 O, which corresponded to total lung capacity (Fig. 3, A-D) .
Individual deflation P-V curves for each animal studied are shown in Fig. 3 , A-D. LPS caused substantial reduction in transthoracic static compliance. Administration of intratracheal LPS into pla2g5 ϩ/ϩ wild-type mice 24 h before measurement caused a rightward shift of P-V curves (Fig. 3B ) compared with baseline P-V curves generated from saline-treated pla2g5 ϩ/ϩ mice (Fig. 3A) . Deletion of the gene encoding gVPLA 2 (Fig.  3C) or blockade with MCL-3G1 (Fig. 3D) significantly blocked the increased lung stiffness caused by LPS. There was no difference between P-V curves generated from LPS-treated KO (pla2g5 Ϫ/Ϫ ) mice (Fig. 3C) vs. wild-type littermate control (pla2g5 ϩ/ϩ ) mice treated with MCL-3G1 before LPS administration (Fig. 3D ), which were both comparable to baseline (no LPS) P-V curves (Fig. 3A) .
For more precise analysis, composite changes in transthoracic static compliance were derived from the linear portion of the P-V curves in each group. Transthoracic static compliance was measured at 10 cmH 2 O (Fig. 3E) . Static compliance in pla2g5 ϩ/ϩ mice decreased by Ϫ0.03 Ϯ 0.004 cmH 2 O after LPS treatment (P Ͻ 0.01 vs. pla2g5 ϩ/ϩ ϩ saline). This reduction in transthoracic static compliance caused by LPS was attenuated to 0.004 Ϯ 0.004 cmH 2 O in gVPLA 2 -deficient mice treated with LPS (P Ͻ 0.01 vs. LPS-treated pla2g5 ϩ/ϩ mice) and to 0.014 Ϯ 0.005 cmH 2 O for pla2g5 ϩ/ϩ mice pretreated with MCL-3G1 before LPS treatment (P Ͻ 0.05 vs. LPStreated pla2g5 ϩ/ϩ mice not pretreated with MAb).
LPS-Increased Lung Fluid (Wet:Dry Weight Ratio)
We also determined the total lung wet:dry (W/D) weight ratio of the excised lungs from all treated groups (Fig. 4) .
Intratracheal instillation of LPS into pla2g5
ϩ/ϩ mice induced an increase in lung fluid at 24 h as reflected in the W/D weight ratio compared with saline-treated mice. The W/D weight ratio, normalized to WT control, increased from 1.0 Ϯ 0.06 (salinetreated) to 1.32 Ϯ 0.02 after LPS stimulation (P Ͻ 0.05). Edema formation was substantially attenuated to a ratio of 1.04 Ϯ 0.05 when LPS was administered to gVPLA 2 KO mice (P Ͻ 0.01 vs. LPS-treated pla2g5 ϩ/ϩ mice; P ϭ not significant vs. saline-treated pla2g5 
LPS-Induced Neutrophilic Inflammation: Histological Examination
Histological examination revealed increased cellular infiltrates in lungs of mice receiving intratracheal LPS (Fig. 5A) ; these changes were much less pronounced in saline-treated pla2g5 ϩ/ϩ mice (Fig. 5B) . Airway neutrophilic inflammation caused by LPS activation was substantially attenuated in gVPLA 2 KO mice (pla2g5 Ϫ/Ϫ ; Fig. 5C ) and in pla2g5 ϩ/ϩ mice treated with MCL-3G1, a MAb directed against gVPLA 2 ( Fig. 5D ) before LPS treatment.
Cell Infiltration in BAL Fluid
Intratracheal instillation of LPS caused pulmonary inflammation characterized by cellular infiltrates into the alveolar space, as reflected by the increased number of neutrophils recovered in the BAL fluid (Fig. 6) . NI was attenuated in gVPLA 2 KO mice and MCL-3G1-treated mice; NI was not observed in saline-treated pla2g5 ϩ/ϩ mice. Quantification of the number of cellular inflammatory cells in BAL was assessed by differential cell counting after Diff-Quick staining (Fig. 6) . LPS alone caused some NI even in pla2g5 Ϫ/Ϫ mice (see DISCUSSION). However, total BAL fluid cell number was greater in LPS-treated pla2g5 ϩ/ϩ littermate controls than pla2g5 LPS-treated pla2g5 ϩ/ϩ mice). Differential cell count demonstrated that neutrophils were the predominant cell type recovered from BAL fluid after LPS (Fig. 6B) . Macrophages increased to a lesser extent, but this difference was not statistically significant (Fig. 6C) . The number of neutrophils in the BAL fluid increased from 0.004 ϫ 10 6 Ϯ 0.003 cells (saline-treated) to 5.07 ϫ 10 6 Ϯ 1.25 cells after LPS administration (P Ͻ 0.01). A Ն50% reduction in neutrophil migration from basal count was observed in LPS-treated KO (pla2g5 Ϫ/Ϫ ) mice (2.43 ϫ 10 6 Ϯ 0.77 cells; P Ͻ 0.05 vs. LPS-treated pla2g5 ϩ/ϩ mice) and 2.95 ϫ 10 6 Ϯ 0.74 cells in pla2g5 ϩ/ϩ treated with MCL-3G1 ϩ LPS (P Ͻ 0.05 vs. LPS-treated pla2g5 ϩ/ϩ mice).
LPS-Increased MPO Activity
MPO content, which is linearly proportional to its activity (see MATERIALS AND METHODS), was substantially increased by LPS in pla2g5 ϩ/ϩ mice and attenuated by specific blockade of gVPLA 2 and in pla2g5 Ϫ/Ϫ mice (Fig. 7A) . Lung MPO concentration, expressed as optical density per 150 g/ml protein (OD), increased to 1.17 Ϯ 0.02 OD after LPS administration compared with 0.15 Ϯ 0.02 OD for saline-treated pla2g5 Neutrophils in BAL fluid were identified as likely the source of MPO as determined by flow cytometric analysis (Fig. 7,  B-D) . Cells contained within the box are granulocytes from BAL fluid after saline or LPS treatment as determined by Gr1, a MAb used to detect the granulocytes including neutrophils. Cells outside the box are other cells in the BAL fluid aside from granulocytes. Granulocytes constituted 88.1% of all cells in the BAL fluid after treatment with LPS. Total cell population in BAL fluid of saline-treated pla2g5 ϩ/ϩ mice showed insignificant numbers of granulocytes (2.04%) as determined by Gr1 MAb staining (Fig. 7C) . The isotype-matched IgG (LPS-treated pla2g5 ϩ/ϩ ϩ PE-IgG antibody) served as control for Gr1 MAb alone and also showed no granulocyte infiltrates in BAL fluid (Fig. 7D) . Histological examination of cytoslides showed that PMNs were the predominant granulocytes increasing in number in pla2g5 ϩ/ϩ mice.
DISCUSSION
The objective of this investigation was to determine the role of the highly hydrolytic phospholipase, gVPLA 2 , in mediating ALI induced by LPS. Studies were performed to assess whether LPS causes upregulation of gVPLA 2 in murine airways. Further studies were performed to determine if this upregulation of gVPLA 2 was responsible for decreased transthoracic static compliance, increased W/D weight ratio, NI, Fig. 3 . Effects of neutralizing MAb against gVPLA2 in wild-type littermate control (pla2g5 ϩ/ϩ ) mice, or gVPLA2 knockout (pla2g5 Ϫ/Ϫ ) mice reduced transthoracic static compliance caused by intratracheal administration of LPS. gVPLA2 littermate control (pla2g5 ϩ/ϩ ) mice were treated with saline (A) or 10 mg/kg LPS (B), and pressure-volume (P-V) curves were generated after 24 h. In other studies, LPS was instilled intratracheally into gVPLA2 knockout (pla2g5 Ϫ/Ϫ ) mice before generation of P-V curves (C). Blockade of decrease in transthoracic lung compliance was measured by pretreating the wildtype (pla2g5 ϩ/ϩ ) mice with MCL-3G1 before LPS administration and P-V curve measurement (D). E: decrease in transthoracic static compliance caused by LPS treatment vs. control. Measurements are means Ϯ SE at 10 cmH2O for each group. Pla2g5 ϩ/ϩ is a saline control group receiving no LPS. *P Ͻ 0.05 compared with LPS-treated pla2g5 ϩ/ϩ mice; **P Ͻ 0.01 compared with LPS-treated pla2g5 ϩ/ϩ mice.
and subsequent neutrophil activation caused by LPS. These physiological and inflammatory effects are commonly used to monitor ALI in animal models of ARDS (11, 21) . We and others (25, 39) previously have shown that gVPLA 2 is secreted from epithelial cells to cause eosinophil activation and surface integrin adhesion of eosinophils to endothelial counterligands in vitro. Immune sensitization also was shown to upregulate gVPLA 2 expression (24). Blockade of gVPLA 2 by specific MAb attenuated substantially this effect in vivo and further blocked airway hyperresponsiveness to methacholine (24) . In preliminary studies with neutrophils, we have demonstrated that gVPLA 2 also is capable of activating neutrophil adhesion (16, 17) . Thus, it is likely that activation of neutrophils caused by this protein results from transport of gVPLA 2 from activated endothelium by LPS. However, neutrophils, epithelium, macrophages, T cells, or airway smooth muscle also contain gVPLA 2 (7, 14, 16, 17, 19, 20, 24) .
Secretory gVPLA 2 has not been shown to be chemotactic, so the in vivo process for initial activation remains undefined. Because of the very small blood volume of mice, it has not been possible to measure directly the concentration of gVPLA 2 after endothelial or epithelial activation in vivo or to determine which tissues participate in gVPLA 2 secretion that can be demonstrated in vitro.
From these studies and others demonstrating that neutrophil cytokines and leukotriene B 4 activate neutrophil adhesion (16, 17, 22) and subsequent migration, we postulated that upregulation and activation of gVPLA 2 by LPS would cause vascular leak and contribute substantially to lung edema in mice. In a first series of studies, we demonstrated that gVPLA 2 content of the lung parenchyma was upregulated substantially within 24 h of exposure to LPS (Fig. 1) . No upregulation of gVPLA 2 content was demonstrated in gVPLA 2 KO mice or in isotype-matched controls. The baseline concentration of mRNA in lungs of littermate controls also was substantially upregulated 24 h after tracheal instillation of LPS (Fig. 2) . These data indicate that LPS causes synthesis and upregulation of gVPLA 2 content within 24 h. Upregulation of gVPLA 2 by LPS also corresponded to decreased transthoracic static compliance (Fig. 3) , which corresponded to an increased W/D weight ratio (Fig. 4) in control mice. The decrease in transthoracic static compliance and increase W/D weight ratio was blocked almost completely by deletion of the gene encoding gVPLA 2 (gVPLA 2 KO mice) and by specific MAb directed against gVPLA 2 (MCL-3G1). These data suggest a substantial role for gVPLA 2 in mediation of the response leading to ALI in this murine model.
We also found that cell infiltrates (predominantly neutrophils) into the small peripheral airways and alveolar spaces caused by LPS was blocked substantially by MAb directed against gVPLA 2 and were substantially attenuated in gVPLA 2 KO mice (Fig. 5) . gVPLA 2 may serve to amplify neutrophil chemotaxis indirectly, possible by activation of smaller numbers of neutrophils elicited by LPS treatment alone (Fig. 6) . A model for this process has been suggested from prior in vitro studies of neutrophil activation by gVPLA 2 (16, 17) . The precise sequence of events in vivo, however, has not yet been elucidated. Nonetheless, blockade of gVPLA 2 by either gVPLA 2 KO or neutralizing MAb against gVPLA 2 substantially attenuated NI caused by LPS. Although substantial, NI was not completely blocked by these processes (Figs. 6 and  7) . The absence of complete blockade of either MPO concentration or all cell migration, even in gVPLA 2 KO mice, suggests that the pathogenesis of neutrophil activation is not linked solely to gVPLA 2 , but may also, to a lesser extent, be caused by LPS alone. Nagase and coworkers (28, 29) demonstrated increased lung elastance in mice treated with hydrochloric acid that was blocked by genetic deletion of the intracellular phospholipase gIVaPLA 2 , which is activated downstream by gVPLA 2 in neutrophils (16, 17) . In these studies, some neutro- phils still were present in gIVaPLA 2 KO mice, even though the indirect measurements of lung compliance were blocked fully and histological sections of lung were similar to those seen in gVPLA 2 KO mice (Fig. 5) . In these studies, we did not establish the downstream mechanism of gVPLA 2 blockade of lung edema caused by LPS. However, it appears that substantial reduction in neutrophil secretion and NI, which is not absolute, may still be sufficient to block the formation of lung edema in ALI.
It is important to consider some further limitations of our findings. These studies are performed in a pathogenetic mouse model, and data cannot be extrapolated to therapeutics in the human situation. We also administered blocking antibody in each study 30 min before LPS administration. It is not clear whether post hoc administration of gVPLA 2 MAb would block edema formation. The purpose of this paper was to determine the possible pathogenetic role of gVPLA 2 as an effector of ALI. Studies examining the potential of gVPLA 2 in preventing incipient or already existent ALI were not performed, as the focus of this study was pathogenesis, not treatment. Such determinations will require administration of gVPLA 2 MAb in wild-type mice over multiple time intervals after LPS administration. We believe it is likely that once substantial lung edema develops, reversal will not be possible. Nonetheless, these studies outline some potential pathogenetic mechanisms for the formation of lung edema through a newly identified messenger protein, gVPLA 2 . Further studies are also required to identify the predominant source of gVPLA 2 , which is induced ( Figs. 1 and 2 ) and upregulated within 24 h in the lung parenchyma following administration of LPS.
We conclude that gVPLA 2 mediates ALI and NI caused by LPS. Blockade of this enzyme or genetic deletion (KO) preventing synthesis of gVPLA 2 blocks substantially the NI and increased lung elastance caused by LPS. The potential role of gVPLA 2 in the prevention or treatment of ALI and NI in animal models and in humans remains to be assessed.
